Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for the treatment of oncology and obesity. Its pipeline features TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1 clinical trials for chronic myeloid leukemia, a cancer originating in the bone marrow. The company also advances TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability, currently in Phase IIa trials for metabolic dysfunction-associated steatohepatitis. Terns Pharmaceuticals maintains a portfolio of single-agent and combination therapies targeting chronic liver diseases, including programs like an FXR agonist, a VAP-1 inhibitor, and a THR-β agonist. These efforts address significant unmet needs in areas such as non-alcoholic steatohepatitis and other metabolic conditions. Founded in 2017 and headquartered in Foster City, California, Terns Pharmaceuticals plays a key role in advancing innovative therapies within the biotechnology sector, emphasizing differentiated candidates for serious diseases.